United Therapeutics | UTHR - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Amarin USD 23.17M 961K 2025-12
Ardelyx USD 114.37M 8.02M 2025-12
Baxter International USD 891M 314M 2026-03
Bayer EUR 6.94B 1.58B 2025-12
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.82B 169.5M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Insmed USD 256.46M 38.78M 2026-03
Ionis Pharmaceuticals USD 243M 48M 2026-03
J&J USD 17.24B 642M 2026-03
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
Moderna USD -566M 792M 2026-03
Omeros USD -33.16M 18.52M 2024-06
Pfizer USD 11.04B 1.24B 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Regeneron Pharmaceuticals USD 2.94B 363.7M 2026-03
Sangamo BioSciences -2.39M 1.09M 2024-06
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Teva Pharmaceutical Industries USD 2.11B 547M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12
Vertex Pharmaceuticals USD 2.6B 121.7M 2026-03